User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8299

Interactions with Platform & by Email *

INTERACTIONS

1162

Unique # Participated *

PARTICIPANTS

249

Responses Validated *

VALIDATIONS

47

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Antiretroviral Drug Market Flourishes.....II-1
US Leads the Global HIV Drugs Market.....II-1
1$100
   NRTIs – The Largest Selling Drug Class Worldwide.....II-2
HIV Prevalence on the Rise.....II-2
Table 1: Global Prevalence of HIV Infection by Region (2007 & 2008) in Millions (includes corresponding Graph/Chart).....II-2
1$350
   Table 2: Global Incidence of HIV Infection by Region (2007 & 2008) in Thousands (includes corresponding Graph/Chart).....II-31$350
   Table 3: Global HIV Related Deaths by Region (2007 & 2008) in Thousands (includes corresponding Graph/Chart).....II-4

Table 4: Global Distribution of HIV Prevalence, Incidence and Mortality (2008) (In Millions) (includes corresponding Graph/Chart).....II-4
1$350
   Table 5: HIV Prevalence in Select Countries (2007) (includes corresponding Graph/Chart).....II-51$350
   Antiretroviral Drugs – The Lone Treatment Option for HIV and AIDS.....II-6
Protease Inhibitors.....II-6
1$100
   Select Protease Inhibitors; Dosing and Frequency.....II-7
Table 6: Leading Protease Inhibitors Drugs Worldwide (2006): Value Sales for Kaletra, Reyataz, Norvir, Agenerase/Lexiva, Viracept and Others (includes corresponding Graph/Chart).....II-7
Overview of Select Protease Inhibitors.....II-7
Kaletra (lopinavir/ritonavir).....II-7
Reyataz (Atazanavir).....II-7
1$350
   Prezista (Darunavir).....II-8
Viracept (nelfinavir mesylate).....II-8
Kaletra and Reyataz to Maintain Market Dominance.....II-8
1$100
   Nucleoside Reverse Transcriptase Inhibitors.....II-9
Approved NRTI Drugs; Dosing and Frequency.....II-9
Overview of Select NRTIs.....II-9
Emtriva (emtricitabine).....II-9
Stavudine (Zerit)– Marred with Safety Issues.....II-9
1$100
   Safety Concerns to Curb Ziagen’s Use.....II-10
Non-Nucleoside Reverse Transcriptase Inhibitors.....II-10
Overview of Select NNRTIs.....II-10
Viramune® (nevirapine).....II-10
Intelence (Etravirine).....II-10
1$100
   Integrase Inhibitors.....II-11
Overview of Select Integrase Inhibitors.....II-11
Isentress (Raltegravir).....II-11
Elvitegravir (Gilead Sciences).....II-11
Chemokine Receptor 5 Inhibitors.....II-11
1$100
   Selzentry (maraviroc).....II-12
Selzentry Makes a Slow Start.....II-12
Fusion Inhibitors.....II-12
Combination Therapy.....II-12
1$100
   Drug Resistance Issues Fuel Use of Combination Therapy.....II-13
Atripla (Bristol-Myers Squibb and Gilead Sciences).....II-13
1$100
   Epzicom (GlaxoSmithKline).....II-14
Quad (Gilead Sciences).....II-14
Drug Pipeline Laden With Efficacious Drugs and Novel Drug Classes.....II-14
1$100
   Abandoned Trials in Recent Years.....II-15
Select Antiretroviral Pipeline Drugs.....II-15
1$100
   HIV Drug Usage Picks Up; Major Population Still Lacks Accessibility.....II-16
ART Penetration Posts Significant Growth in Recent Years.....II-16
1$100
   Table 7: HIV-Infected Population Receiving Anti-Retroviral Treatment in Low and Middle Income Countries (2004 - 2008) (In Millions) (includes corresponding Graph/Chart).....II-17

Table 8: HIV-Infected Population Receiving and In Need of Anti-Retroviral Treatment in Low and Middle Income Countries By Region (2008) (includes corresponding Graph/Chart).....II-17
1$350
   Table 9: Number of HIV Patients Receiving Antiretroviral Drugs in Select Low- and Middle-Income Countries (2008) (includes corresponding Graph/Chart).....II-181$350
   Table 10: Number of HIV Patients Receiving Antiretroviral Drugs in Select Low- and Middle- Income Countries By Gender (2008) (includes corresponding Graph/Chart).....II-191$350
   Table 11: Number of HIV Patients Receiving Antiretroviral Drugs in Select Low- and Middle-Income Countries By Age Group (2008).....II-201$350
   Table 12: Number of HIV Patients Receiving Antiretroviral Drugs in Select High-Income Countries (2008) (includes corresponding Graph/Chart).....II-21
Number of Children and Pregnant Women on ART Rises Dramatically.....II-21
1$350
   Table 13: HIV-Infected Children Receiving and In Need of Anti-Retroviral Treatment in Low and Middle Income Countries By Region (2008) (includes corresponding Graph/Chart).....II-221$350
   Table 14: HIV-Infected Pregnant Women Receiving and In Need of Anti-Retroviral Treatment in Low and Middle Income Countries By Region (2008) (includes corresponding Graph/Chart).....II-23
Convenience and Efficacy – Key Growth Drivers.....II-23
1$350
   Antiretrovirals as Preventive Medicine.....II-24
Cost of ARTs – A Major Barrier to Widespread Access.....II-24
Manufacturers Hindering Entry of Generics.....II-24
1$100
   Indian Drug Manufactures Propose to Offer Low Cost Generic Versions.....II-25
Need for Novel Drugs Continues.....II-25
Development of Vaccines for HIV – A Challenging Task.....II-25
1$100
   Immune-Based Therapies Bode Promising Treatment Options for Future.....II-26
Injecting Drug Users and HIV.....II-26
1$100
   HIV Drug Industry - Rife With Activity.....II-27
Gilead Reaches the Top, While GSK Scrambles to Gain Lost Ground.....II-27
1$100
   Table 15: Leading Companies in Global HIV Drugs Market (2005, 2007 & 2009): Percentage Breakdown of Revenues for Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb and Others (includes corresponding Graph/Chart).....II-28
Truvada Reigns Global HIV Drug Market; Atripla Fast Catching Up.....II-28
1$350
   Table 16: Worldwide Sales of Select Leading HIV Drugs (2006-2008) (includes corresponding Graph/Chart).....II-29
Atripla to Ease Truvada’s Revenue Growth.....II-29
1$350
   Atripla’s Success Propels Gilead’s Market Share Above GSK.....II-301$100
   HIV – An Overview of the Deadly Virus.....II-31
Unique Genetic Variability of HIV.....II-31
1$100
   Origin of HIV.....II-321$100
   Types of HIV Virus.....II-33
HIV Transmission.....II-33
Sexual Route.....II-33
Blood Products or Blood.....II-33
Mother-to-Child.....II-33
1$100
   Human Immune System and HIV Interaction.....II-34
Stages of HIV Infection.....II-34
Acute Stage of HIV Infection.....II-34
1$100
   Latency Stage.....II-35
AIDS – Acquired Immune Deficiency Syndrome.....II-35
1$100
   Symptoms of HIV and AIDS Infection.....II-36
HIV Testing.....II-36
1$100
   Diagnostic Tests for HIV and AIDS Infection.....II-371$100
   HIV Treatment.....II-381$100
   Pfizer Obtains Expanded Indication for Selzentry from FDA.....II-39
Tibotec Obtains Traditional Approval for Intelence®.....II-39
FDA Confers Tentative Approval for Generic Efavirenz Tablets.....II-39
1$100
   FDA Clears New Dosing Recommendations for Retrovir Syrup for Infants.....II-40
FDA Confers Tentative Approval for Lamivudine and Tenofovir df Tablets.....II-40
Abbott Obtains EC Approval for Once-daily Dosage of Kaletra®.....II-40
1$100
   Merck Obtains Expanded indication for Isentress®, for use in Treatment-Naïve HIV
  Patients.....II-41
Tibotec Obtains FDA Clearance for Using Prezista in Pediatric Patients.....II-41
Tibotec Obtains EU Approval for Once-daily Dosing of Prezista.....II-41
1$100
   Pfizer Receives FDA Clearance for Marketing Selzentry™.....II-42
BMS Obtains FDA Approval for REYATAZ®/r Combination Therapy.....II-42
EU Clears Tibotec’s Intelence™ in HIV Combination Therapy.....II-42
Boehringer Obtains FDA Approval for Aptivus® OS.....II-42
1$100
   Abbott Obtains EC Approval for Lower-Strength Kaletra for Pediatric Use.....II-431$100
   Gilead Completes Phase II Trial on Single-Dose HIV Drug, Quad.....II-44
Gilead Completes Phase II Trial on Cobicistat Boosting Agent, Cobicista.....II-44
1$100
   Merck to Refrain from Filing NDA for Vicriviroc in Treatment-Experienced
  HIV-Patients.....II-45
Merck’s Isentress® Receives U.S. DHHS Recommendation for Use in Treatment- Naïve
  Patients.....II-45
GSK and Pfizer Launch ViiV Healthcare.....II-45
1$100
   GSK and Idenix to Co-Develop New HIV Drug.....II-46
Avexa Enters into Agreement with Tibotec.....II-46
Gilead Enters into Agreement with Piramal Lifesciences.....II-46
Avexa to Merge with Progen.....II-46
1$100
   Myriad Acquires Bevirimat.....II-47
Vironova Signs Agreement with UMBC.....II-47
Ceragenix Signs License Agreement with FPBT.....II-47
Medivir to Transfer Alovudine License and IP to Beijing Mefuvir.....II-47
1$100
   Gilead Sciences and Merck Ink Distributing Agreement for Atripla.....II-48
Boehringer Commences New Clinical Trial for Viramune® XR.....II-48
EC Reinstates Marketing Authorization for Viracept.....II-48
1$100
   Virax Bags Additional Patent for HIV Vaccine, VIR201.....II-491$100
   Abbott Laboratories (US).....II-50
Boehringer Ingelheim GmbH (Germany).....II-50
1$100
   Bristol-Myers Squibb Company (US).....II-511$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-52
Gilead Sciences, Inc. (US).....II-52
Koronis Pharmaceuticals, Inc. (US).....II-52
1$100
   Merck & Co., Inc. (US).....II-53
Pfizer, Inc. (US).....II-53
1$100
   Tibotec BVBA (Belgium).....II-54
ViiV Healthcare (UK).....II-54
1$100
   VIRxSYS Corp. (US).....II-551$100
   Table 17: World Recent Past, Current & Future Analysis for HIV Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-561$350
   Table 18: World 10-Year Perspective for HIV Drugs by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe and Rest of World Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart).....II-571$350
   Table 19: World Recent Past, Current & Future Analysis for HIV Drugs by Product Segment - NRTIs, NNRTIs, PIs and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-581$350
   Table 20: World 10-Year Perspective for HIV Drugs by Product Segment - Percentage Breakdown of Dollar Revenues for NTRIs, NNTRIs, PIs and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart).....II-591$350
   A. Market Analysis.....III-1
HIV Drugs Market Continues to Prosper.....III-1
NRTIs Maintain the Lead.....III-1
Select FDA–Approved Antiretroviral Drugs and Approval Date.....III-1
2$125
   Patent Expiries of Select Antiretroviral Drugs in the US (2010 and Beyond).....III-31$75
   Atripla Tops US HIV Drug Chart.....III-4
Table 21: Leading HIV/AIDS Drugs in the US Market (2008) in US$ Million (includes corresponding Graph/Chart).....III-4
1$200
   NRTIs Losing Share In Total Prescriptions; Top Spot Remains Intact.....III-5
Table 22: Percentage Breakdown of US Total Prescriptions of HIV Drugs By Class (2004-2008) (includes corresponding Graph/Chart).....III-5
Gilead Takes the Lead In NRTI Prescriptions.....III-5
1$200
   Table 23: Percentage Breakdown of US Total Prescriptions of NRTIs By Company (2004-2007) (includes corresponding Graph/Chart).....III-61$200
   Table 24: Percentage Breakdown of US Total Prescriptions of NRTIs By Drug (2006-2007) (includes corresponding Graph/Chart).....III-7
Atripla Leads in Treatment-Naïve HIV Market.....III-7
Table 25: Leading Drugs in Treatment-Naive HIV Patient Therapeutic Market (2007) (includes corresponding Graph/Chart).....III-7
1$200
   Patent Expiries to Dent Sales of GSK.....III-8
Drug Assistance Programs Take the Brunt of Recession.....III-8
New Drug Approvals.....III-8
3$175
   Strategic Corporate Developments.....III-113$175
   Select Players in the Region.....III-144$225
   B. Market Analytics.....III-18
Table 26: US Recent Past, Current & Future Analysis for HIV Drugs by Product Segment - NRTIs, NNRTIs, PIs and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   Table 27: US 10-Year Perspective for HIV Drugs by Product Segment - Percentage Breakdown of Dollar Revenues for NTRIs, NNTRIs, PIs and Others Markets for Years 2006, 2009, & 2015 (includes corresponding Graph/Chart).....III-191$200
   A. Market Analysis.....III-20
Current and Future Analysis.....III-20
Approval Delays Daunting Drug Access.....III-20
A Peek into the Canadian Drug Regulatory Environment.....III-20
PI Drugs Continue to Witness Growth.....III-20
1$75
   Table 28: Canadian Sales of Protease Inhibitor Drugs (2007 & 2008) in US$ Million (includes corresponding Graph/Chart).....III-21
Select Approved Antiretroviral Drugs in Canada (1995-2006).....III-21
1$200
   B. Market Analytics.....III-22
Table 29: Canadian Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-22
1$200
   A. Market Analysis.....III-23
Japan – The Fastest Growing Market for HIV Drugs Worldwide.....III-23
Funding Scenario in Japan.....III-23
1$75
   B. Market Analytics.....III-24
Table 30: Japanese Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-24
1$200
   A. Market Analysis.....III-25
Demand for HIV Drugs Continues to Rise.....III-25
European HIV Drug Market – An Overview.....III-25
Delayed Diagnosis – A Major Impediment to Increase in Survival.....III-25
1$75
   Limiting Factors Hitting Growth Prospects Hard.....III-26
Number of New Patients Rises, While Discontinuation Rates Plummet in Leading
  Markets.....III-26
1$75
   Table 31: HIV Drugs Market in Leading EU Countries (2006): Percentage Breakdown for Italy, Spain, France, United Kingdom and Germany (includes corresponding Graph/Chart).....III-27
HAART Continues to Gain Market Share.....III-27
New Drug Approvals.....III-27
2$200
   Strategic Corporate Developments.....III-292$125
   Select Players in the Region.....III-313$175
   B. Market Analytics.....III-34
Table 32: European Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-34
1$200
   A. Market Analysis.....III-35
Current and Future Analysis.....III-35
Funding Gap Threatens to Put Patients at Risk.....III-35
Drugs Resistance Prompts Chinese Government to Launch Novel Drugs.....III-35
1$75
   Strategic Corporate Developments.....III-36
B. Market Analytics.....III-36
Table 33: Rest of World Recent Past, Current & Future Analysis for HIV Drugs with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-36
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com